Oxaliplatin - Uses, Dosage, Side Effects, Interaction

Oxaliplatin is an intravenously administered platinum-containing alkylating agent which is used for the treatment of advanced colorectal cancer. Oxaliplatin therapy is associated with a low rate of transient serum aminotransferase elevations but is commonly associated with sinusoidal and vascular injury to the liver which can lead to sinusoidal obstruction syndrome and to nodular regenerative hyperplasia with noncirrhotic portal hypertension.

Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a ‘leaving group.’ A ‘leaving group’ is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After the displacement of the labile oxalate, ligand leaving group, active oxaliplatin derivatives, such as monocoque and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)

Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyl diamine for improved antitumor activity. The chlorine ligands are replaced by the oxalate bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin.

Oxaliplatin is a platinum coordination entity that is a commonly used chemotherapeutic drug for the treatment of colorectal cancer. It has a role as an antineoplastic agent and a mutagen. An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane, and with an oxalate ligand which is displaced to yield active oxaliplatin derivatives. These derivatives form inter and intra-strand DNA crosslinks that inhibit DNA replication and transcription. Oxaliplatin is an antineoplastic agent that is often administered with FLUOROURACIL and FOLINIC ACID in the treatment of metastatic COLORECTAL NEOPLASMS.

Mechanism of Action

Oxaliplatin undergoes nonenzymatic conversion to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including Monaco and diaquo DACH platinum, which covalently bind with macromolecules. After activation, oxaliplatin binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and transcription. Cytotoxicity is cell-cycle nonspecific.

Oxaliplatin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Oxaliplatin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.

The compound features a square planar platinum(II) center. In contrast to other drugs of the platinum-based antineoplastic class of drugs cisplatin and carboplatin, oxaliplatin features the bidentate ligand trans-1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group. The three-dimensional structure of the molecule has been elucidated by X-ray crystallography, although the presence of pseudosymmetry in the crystal structure has caused confusion in its interpretation.

According to in vivo studies, oxaliplatin fights carcinoma of the colon through non-targeted cytotoxic effects. Like other platinum compounds, its cytotoxicity is thought to result from the inhibition of DNA synthesis in cells. In particular, oxaliplatin forms both inter- and intra-strand cross-links in DNA,^[rx] which prevent DNA replication and transcription, causing cell death.

Indications

Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
Oxaliplatin is approved to be used with fluorouracil and leucovorin calcium to treat: Colorectal cancer that is advanced Stage III colon cancer. It is used after surgery to remove cancer.
Advanced Colorectal Cancer
Stage III Colon Cancer

Contraindication

low amount of magnesium in the blood
low amount of potassium in the blood
anemia
decreased blood platelets
low levels of a type of white blood cell called neutrophils
a painful condition that affects the nerves in the legs and arms called peripheral neuropathy
abnormal EKG with QT changes from birth
a type of inflammation of the lung called interstitial pneumonitis
a condition where there is formation of fibrous tissue in the lung called pulmonary fibrosis
abnormal liver function tests
pregnancy
a patient who is producing milk and breastfeeding
muscle pain or tenderness with increase creatine kinase
a type of brain disorder called posterior reversible encephalopathy syndrome
chronic kidney disease stage 4 (severe)
chronic kidney disease stage 5 (failure)

Dosage

Strengths: 5 mg/mL; 50 mg; 100 mg

Colorectal Cancer

85 mg/m2 via IV infusion over 120 minutes every 2 weeks; administer in combination with infusional 5-fluorouracil and leucovorin.

Duration of Therapy

Adjuvant Treatment of Stage III Colon Cancer: Total of 6 months (12 cycles)
Treatment of Advanced Colorectal Cancer: Until disease progression or unacceptable toxicity
Premedication with antiemetics, including 5-HT3 blockers with or without dexamethasone, is recommended.
Consult the manufacturer product information for 5-fluorouracil and leucovorin dosing recommendations.
Uses In combination with infusional 5-fluorouracil and leucovorin:
Adjuvant treatment of Stage III colon cancer in patients who have undergone complete resection of the primary tumor.
Treatment of advanced colorectal cancer.

Renal Dose Adjustments

Mild to Moderate Renal Impairment (CrCl 30 to 80 mL/min): No adjustment recommended.
Severe Renal Impairment (CrCl less than 30 mL/min): Reduce dose to 65 mg/m2.

Dose Adjustments

ACUTE TOXICITIES: Consider prolonging the infusion time for this drug from 2 hours to 6 hours.

AFTER RECOVERY FROM GRADE 3/4 GASTROINTESTINAL TOXICITY (DESPITE PROPHYLACTIC TREATMENT)

Adjuvant Treatment of Stage III Colon Cancer: 75 mg/m2
Treatment of Advanced Colorectal Cancer: 65 mg/m2

GRADE 4 NEUTROPENIA, FEBRILE NEUTROPENIA, OR GRADE 3/4 THROMBOCYTOPENIA: Reduce the dose and delay the next dose until neutrophils 1.5 x 10(9)/L or greater and platelets 75 x 10(9)/L or greater.

Adjuvant Treatment of Stage III Colon Cancer: 75 mg/m2
Treatment of Advanced Colorectal Cancer: 65 mg/m2

NEUROSENSORY EVENTS
GRADE 2: Consider reducing the dose.

Adjuvant Treatment of Stage III Colon Cancer: 75 mg/m2
Treatment of Advanced Colorectal Cancer: 65 mg/m2

GRADE 3: Consider treatment discontinuation (for both indications).

Administration Advice

Dilute this drug before administration; consult the manufacturer’s product information for dilution instructions.
Consult the manufacturer’s product information for infusion instructions.
Do not use needles or IV administration sets containing aluminum parts since aluminum has been reported to cause the degradation of platinum compounds.
Immediately discontinue drug administration and initiate usual local symptomatic treatment in the event of extravasation.
Prior to administration, visually inspect for particulate matter and discoloration and discard if present.
Prior to subsequent therapy cycles, evaluate patients for clinical toxicities and recommended laboratory tests.
The administration of this drug does not require prehydration.

Storage Requirements

After dilution, the shelf life of this drug is 6 hours at room temperature (20 to 25 degrees Celsius/68 to 77 degrees Fahrenheit) or up to 24 hours under refrigeration (2 to 8 degrees Celsius/36 to 46 degrees Fahrenheit).
Retain this drug in its original package until the time of use. Do not freeze and protect from light; however, the final diluted drug does not need protection from light.

Reconstitution/Preparation Techniques

Exercise care and use gloves when handling this drug. If a solution of this drug contacts the skin or mucous membranes, wash the skin immediately with soap and water and flush the mucous membranes thoroughly with water.

IV Compatibility

Do not mix or administer this drug simultaneously through the same infusion line with alkaline medications or media (e.g., basic solutions of 5-fluorouracil, folinic acid preparations containing trometamol, trometamol salts of other active substances) as alkaline products will adversely affect the stability of this drug.
Reconstitution/final dilution of this drug should not be performed with saline or other solutions containing chloride ions (including sodium, calcium, or potassium chloride).
Consult the manufacturer product information for additional IV compatibilities and incompatibilities.

General

Overdosage: No known antidote.

Monitoring

Monitor a full blood count with white cell differential, hemoglobin, platelet count, and blood chemistries (including ALT, AST, bilirubin, and creatinine) prior to treatment initiation and before each subsequent treatment cycle.
Monitor neurological toxicity; perform a neurological examination before each administration and periodically thereafter.

Patient Advice

Avoid potentially dangerous activities such as driving and operating machinery until you know how this drug affects you.

Side Effects

The Most Common

Numbness, burning, or tingling in the fingers, toes, hands, feet, mouth, or throat
Neurotoxicity leads to chemotherapy-induced peripheral neuropathy, a progressive, enduring, and often irreversible tingling numbness, intense pain, and hypersensitivity to cold, beginning in the hands and feet and sometimes involving the arms and legs, often with deficits in proprioception. This chronic neuropathy may also be preceded by a transient acute neuropathy occurring at the time of infusion and associated with the excitation of voltage-gated Na⁺ channels.
Fatigue
Nausea, vomiting, or diarrhea
Neutropenia (low number of a type of white blood cells)
Ototoxicity (hearing loss)
Extravasation if oxaliplatin leaks from the infusion vein may cause severe damage to the connective tissues.
Hypokalemia (low blood potassium), which is more common in women than men
Persistent hiccups
pain in the hands or feet
increased sensitivity, especially to cold
decreased sense of touch
nausea
vomiting
diarrhea
constipation
gas
stomach pain
heartburn
sores in the mouth
loss of appetite
change in the ability to taste food
weight gain or loss
hiccups
dry mouth
muscle, back, or joint pain
tiredness
anxiety
depression
difficulty falling asleep or staying asleep
hair loss
dry skin
redness or peeling of the skin on the hands and feet
sweating
flushing

More Common

stumbling or loss of balance when walking
difficulty with everyday activities such as writing or fastening buttons
difficulty speaking
strange feeling in the tongue
tightening of the jaw
chest pain or pressure
cough
shortness of breath
sore throat, fever, chills, and other signs of infection
pain, redness, or swelling in the place where oxaliplatin was injected
pain when urinating
decreased urination
unusual bruising or bleeding
nosebleed
blood in urine
vomit that is bloody or looks like coffee grounds
bright red blood in stool
black and tarry stools
pale skin
weakness
problems with vision
swelling of the arms, hands, feet, ankles, or lower legs

Rare

chills or shivering
burning or pain on urination
pain on swallowing
redness or swelling at the intravenous site
sore throat
persistent diarrhea
cough that brings up mucus
Leukemia, a form of blood cancer, has been reported in patients after taking oxaliplatin in combination with certain other medicines.
Lung problems. Oxaliplatin can cause lung problems that may lead to death. Tell your doctor right away if you get any of the following symptoms as these may be indicators of serious lung disease: shortness of breath, cough, wheezing
Liver problems (hepatotoxicity). Your doctor will do blood tests to check your liver when you start receiving oxaliplatin, and before each treatment course as needed.
Heart problems. Oxaliplatin can cause heart problems that have led to death. Your doctor may do blood and heart tests during treatment with oxaliplatin if you have certain heart problems. If you faint (lose consciousness) or have an irregular heartbeat or chest pain during treatment with oxaliplatin, get medical help right away as this may be a sign of a serious heart condition.
Muscle problems. Oxaliplatin can cause muscle damage (rhabdomyolysis) which can lead to death. Tell your doctor right away if you have muscle pain and swelling, along with weakness, fever, or red-brown urine.
Harm to an unborn baby.
Bleeding problems (hemorrhage). Oxaliplatin when used with fluorouracil and leucovorin can cause bleeding problems (hemorrhage) that can lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs or symptoms of bleeding, including:
- blood in your stools or black stools (looks like tar)
- pink or brown urine
- unexpected bleeding, or bleeding that is severe or you cannot control
- vomit blood or vomit that looks like coffee grounds
- cough up blood or blood clots
- increased bruising
- dizziness
- weakness
- confusion
- changes in speech
- headache that lasts a long time

Drug Interaction

DRUG	INTERACTION
Abatacept	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Abatacept.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Oxaliplatin.
Abemaciclib	Abemaciclib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Acenocoumarol	The risk or severity of bleeding can be increased when Acenocoumarol is combined with Oxaliplatin.
Acetylsalicylic acid	The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Oxaliplatin.
Acrivastine	The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Oxaliplatin.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Oxaliplatin.
Adenosine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Adenosine.
Adenovirus	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Oxaliplatin.
Afatinib	Afatinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Ajmaline	The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Oxaliplatin.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Oxaliplatin.
Alectinib	Alectinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Oxaliplatin.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Oxaliplatin.
Alfuzosin	The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Oxaliplatin.
Alimemazine	The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Oxaliplatin.
Allogeneic	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Oxaliplatin.
Allopurinol	The risk or severity of adverse effects can be increased when Allopurinol is combined with Oxaliplatin.
Alteplase	The risk or severity of bleeding can be increased when Alteplase is combined with Oxaliplatin.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Oxaliplatin.
Amantadine	The serum concentration of Oxaliplatin can be increased when it is combined with Amantadine.
Amifampridine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Amifampridine.
Amiloride	The serum concentration of Oxaliplatin can be increased when it is combined with Amiloride.
Aminohippuric acid	The serum concentration of Oxaliplatin can be increased when it is combined with Aminohippuric acid.
Amiodarone	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Amiodarone.
Amisulpride	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Amisulpride.
Amitriptyline	The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Oxaliplatin.
Amodiaquine	The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Oxaliplatin.
Amoxapine	The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Oxaliplatin.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Oxaliplatin.
Anagrelide	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Anagrelide.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Oxaliplatin.
Ancrod	The risk or severity of bleeding can be increased when Ancrod is combined with Oxaliplatin.
Anifrolumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Anifrolumab.
Anistreplase	The risk or severity of bleeding can be increased when Anistreplase is combined with Oxaliplatin.
Antazoline	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Antazoline.
Anthrax immune	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Oxaliplatin.
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Oxaliplatin.
Antilymphocyte	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Antilymphocyte immunoglobulin (horse).
Antithrombin Alfa	The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Oxaliplatin.
Antithrombin III human	The risk or severity of bleeding can be increased when Antithrombin III human is combined with Oxaliplatin.
Antithymocyte	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Oxaliplatin.
Apalutamide	The serum concentration of Oxaliplatin can be increased when it is combined with Apalutamide.
Apixaban	The risk or severity of bleeding can be increased when Apixaban is combined with Oxaliplatin.
Apomorphine	The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Oxaliplatin.
Apremilast	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Apremilast.
Ardeparin	The risk or severity of bleeding can be increased when Ardeparin is combined with Oxaliplatin.
Arformoterol	The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Oxaliplatin.
Argatroban	The risk or severity of bleeding can be increased when Argatroban is combined with Oxaliplatin.
Aripiprazole	The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Oxaliplatin.
Aripiprazole lauroxil	The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Oxaliplatin.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Arsenic trioxide.
Artemether	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Artemether.
Articaine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Articaine.
Asenapine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Asenapine.
Astemizole	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Astemizole.
COVID-19 Vaccine	The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Oxaliplatin.
Atazanavir	The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Oxaliplatin.
Atomoxetine	The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Oxaliplatin.
Atropine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Atropine.
Avanafil	Avanafil may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Avatrombopag	Avatrombopag may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Azacitidine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Azacitidine.
Azatadine	The risk or severity of QTc prolongation can be increased when Azatadine is combined with Oxaliplatin.
Azathioprine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Azathioprine.
Azithromycin	The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Oxaliplatin.
Bacillus connaught	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Oxaliplatin.
Guerin substrain russian	The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Oxaliplatin.
Bacillus calmette	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Oxaliplatin.
Baricitinib	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Baricitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Oxaliplatin.
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Oxaliplatin.
Beclomethasone	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Oxaliplatin.
Bedaquiline	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Bedaquiline.
Belatacept	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Belatacept.
Belimumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Belimumab.
Belinostat	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Belinostat.
Belumosudil	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Belumosudil.
Bemiparin	The risk or severity of bleeding can be increased when Bemiparin is combined with Oxaliplatin.
Bendamustine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bendamustine.
Bendroflumethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Oxaliplatin.
Benzatropine	The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Oxaliplatin.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Benzocaine.
Benzthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Oxaliplatin.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Benzyl alcohol.
Bepridil	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Bepridil.
Berotralstat	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Berotralstat.
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Oxaliplatin.
Betrixaban	The risk or severity of bleeding can be increased when Betrixaban is combined with Oxaliplatin.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Oxaliplatin.
Bilastine	The risk or severity of QTc prolongation can be increased when Bilastine is combined with Oxaliplatin.
Bimekizumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bimekizumab.
Bivalirudin	The risk or severity of bleeding can be increased when Bivalirudin is combined with Oxaliplatin.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Oxaliplatin.
Blinatumomab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Blinatumomab.
Bordetella	The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Oxaliplatin.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Oxaliplatin.
Bosutinib	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bosutinib.
Brentuximab vedotin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Brentuximab vedotin.

You Might Also Read Tretinoin Gel - Uses, Dosage, Side Effects, Interactions

Desipramine	The serum concentration of Oxaliplatin can be increased when it is combined with Desipramine.
Desirudin	The risk or severity of bleeding can be increased when Desirudin is combined with Oxaliplatin.
Desloratadine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Desloratadine.
Desoximetasone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Desoximetasone.
Deucravacitinib	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Deucravacitinib.
Deutetrabenazine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Deutetrabenazine.
Dexamethasone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dexamethasone.
Dexamethasone acetate	Dexamethasone acetate may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Dexbrompheniramine	The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Oxaliplatin.
Dexchlorpheniramine	The serum concentration of Oxaliplatin can be increased when it is combined with Dexchlorpheniramine maleate.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Oxaliplatin.
Dextran	The risk or severity of bleeding can be increased when Dextran is combined with Oxaliplatin.
Dicoumarol	The risk or severity of bleeding can be increased when Dicoumarol is combined with Oxaliplatin.
Diethylstilbestrol	Diethylstilbestrol may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Difluocortolone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Difluocortolone.
Digitoxin	The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Oxaliplatin.
Digoxin	The risk or severity of QTc prolongation can be increased when Digoxin is combined with Oxaliplatin.
Diltiazem	The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Oxaliplatin.
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dimenhydrinate.
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dimethyl fumarate.
Dinoprostone	The serum concentration of Oxaliplatin can be increased when it is combined with Dinoprostone.
Dinutuximab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dinutuximab.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Diphenhydramine.
Dipyridamole	The risk or severity of bleeding can be increased when Dipyridamole is combined with Oxaliplatin.
Diroximel fumarate	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Diroximel fumarate.
Disopyramide	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Disopyramide.
Disulfiram	The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Oxaliplatin.
Docetaxel	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Docetaxel.
Dofetilide	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dofetilide.
Dolasetron	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dolasetron.
Dolutegravir	The serum concentration of Oxaliplatin can be increased when it is combined with Dolutegravir.
Domperidone	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Domperidone.
Dopamine	The serum concentration of Oxaliplatin can be increased when it is combined with Dopamine.
Dosulepin	The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Oxaliplatin.
Doxepin	The risk or severity of QTc prolongation can be increased when Doxepin is combined with Oxaliplatin.
Doxorubicin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Doxorubicin.
Doxylamine	The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Oxaliplatin.
Dronedarone	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dronedarone.
Droperidol	The risk or severity of QTc prolongation can be increased when Droperidol is combined with Oxaliplatin.
Drotrecogin alfa	The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Oxaliplatin.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Dyclonine.
Ebastine	The risk or severity of QTc prolongation can be increased when Ebastine is combined with Oxaliplatin.
Ebola Zaire	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Oxaliplatin.
Eculizumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Eculizumab.
Edetic acid	The risk or severity of bleeding can be increased when Edetic acid is combined with Oxaliplatin.
Edoxaban	The risk or severity of bleeding can be increased when Edoxaban is combined with Oxaliplatin.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Oxaliplatin.
Efavirenz	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Efavirenz.
Elbasvir	Elbasvir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Eliglustat	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Eliglustat.
Eltrombopag	Eltrombopag may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Emapalumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Emapalumab.
Emedastine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Emedastine.
Enasidenib	The serum concentration of Oxaliplatin can be increased when it is combined with Enasidenib.
Encainide	The risk or severity of QTc prolongation can be increased when Encainide is combined with Oxaliplatin.
Encorafenib	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Encorafenib.
Enoxacin	The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Oxaliplatin.
Enoxaparin	The risk or severity of bleeding can be increased when Enoxaparin is combined with Oxaliplatin.
Entrectinib	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Entrectinib.
Epinastine	The risk or severity of QTc prolongation can be increased when Epinastine is combined with Oxaliplatin.
Epinephrine	The serum concentration of Oxaliplatin can be increased when it is combined with Epinephrine.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Oxaliplatin.
Epoprostenol	The risk or severity of bleeding can be increased when Epoprostenol is combined with Oxaliplatin.
Eptifibatide	The risk or severity of bleeding can be increased when Eptifibatide is combined with Oxaliplatin.
Erdafitinib	The serum concentration of Oxaliplatin can be increased when it is combined with Erdafitinib.
Eribulin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Eribulin.
Erlotinib	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Erlotinib.
Erythromycin	The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Oxaliplatin.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Oxaliplatin.
Escitalopram	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Escitalopram.
Esmolol	The risk or severity of QTc prolongation can be increased when Esmolol is combined with Oxaliplatin.
Estradiol	The serum concentration of Oxaliplatin can be increased when it is combined with Estradiol.
Estradiol acetate	The serum concentration of Oxaliplatin can be increased when it is combined with Estradiol acetate.
Estradiol benzoate	The serum concentration of Oxaliplatin can be increased when it is combined with Estradiol benzoate.
Estradiol cypionate	The serum concentration of Oxaliplatin can be increased when it is combined with Estradiol cypionate.
Estradiol dienanthate	The serum concentration of Oxaliplatin can be increased when it is combined with Estradiol dienanthate.
Estradiol valerate	The serum concentration of Oxaliplatin can be increased when it is combined with Estradiol valerate.
Estramustine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Estramustine.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Oxaliplatin.
Ethosuximide	The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Oxaliplatin.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Etidocaine.
Etoposide	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Etoposide.
Everolimus	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Everolimus.
Ezogabine	The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Oxaliplatin.
Famotidine	The serum concentration of Oxaliplatin can be increased when it is combined with Famotidine.
Famtozinameran	The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Oxaliplatin.
Febuxostat	The excretion of Oxaliplatin can be decreased when combined with Febuxostat.
Fedratinib	Fedratinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Felbamate	The risk or severity of QTc prolongation can be increased when Felbamate is combined with Oxaliplatin.
Felodipine	The risk or severity of QTc prolongation can be increased when Felodipine is combined with Oxaliplatin.
Fexinidazole	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fexinidazole.
Filgotinib	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Filgotinib.
Fingolimod	Oxaliplatin may increase the immunosuppressive activities of Fingolimod.
Flecainide	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Flecainide.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Oxaliplatin.
Fluconazole	The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Oxaliplatin.
Flucytosine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Flucytosine.
Fludarabine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fludarabine.
Fludrocortisone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fludrocortisone.

Fluindione	The risk or severity of bleeding can be increased when Fluindione is combined with Oxaliplatin.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Oxaliplatin.
Fluocinolone acetonide	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluocinolone acetonide.
Fluocinonide	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluocinonide.
Fluocortolone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluocortolone.
Fluorometholone	The risk or severity of adverse effects can be increased when Fluorometholone is combined with Oxaliplatin.
Fluorouracil	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluorouracil.
Fluoxetine	The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Oxaliplatin.
Flupentixol	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Flupentixol.
Fluprednisolone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluprednisolone.
Flurazepam	The serum concentration of Oxaliplatin can be increased when it is combined with Flurazepam.
Fluspirilene	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Fluspirilene.
Fluticasone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluticasone.
Fluticasone furoate	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluticasone furoate.
Fluticasone propionate	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluticasone propionate.
Fondaparinux	The risk or severity of bleeding can be increased when Fondaparinux is combined with Oxaliplatin.
Formoterol	The risk or severity of QTc prolongation can be increased when Formoterol is combined with Oxaliplatin.
Foscarnet	The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Oxaliplatin.
Fosphenytoin	Oxaliplatin can cause a decrease in the absorption of Fosphenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fostamatinib	Fostamatinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Fostemsavir	Fostemsavir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Fusidic acid	Fusidic acid may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Gadobenic acid	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Gadobenic acid.
Galantamine	The risk or severity of QTc prolongation can be increased when Galantamine is combined with Oxaliplatin.
Gallium nitrate	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Gallium nitrate.
Gatifloxacin	The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Oxaliplatin.
Gefitinib	Gefitinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Oxaliplatin.
Gemifloxacin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Gemifloxacin.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Oxaliplatin.
Gilteritinib	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Gilteritinib.
Glasdegib	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Glasdegib.
Glatiramer	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Glatiramer.
Glecaprevir	Glecaprevir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Golimumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Golimumab.
Goserelin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Oxaliplatin.
Granisetron	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Granisetron.
Grazoprevir	Grazoprevir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Grepafloxacin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Grepafloxacin.
Guanidine	The serum concentration of Oxaliplatin can be increased when it is combined with Guanidine.
Guselkumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Guselkumab.
Haemophilus	The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Oxaliplatin.
Halofantrine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Halofantrine.
Haloperidol	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Haloperidol.
Heparin	The risk or severity of bleeding can be increased when Heparin is combined with Oxaliplatin.
Hepatitis A Vaccine	The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Oxaliplatin.
Hepatitis B Vaccine	The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Oxaliplatin.
Histamine	The serum concentration of Oxaliplatin can be increased when it is combined with Histamine.
Histrelin	The risk or severity of QTc prolongation can be increased when Histrelin is combined with Oxaliplatin.
Human adenovirus	The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Oxaliplatin.
Hydrochlorothiazide	The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Oxaliplatin.
Hydrocortisone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydrocortisone acetate.
Hydrocortisone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydrocortisone butyrate.
Hydrocortisone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydrocortisone succinate.
Hydroflumethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Oxaliplatin.
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydroxychloroquine.
Hydroxyurea	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Hydroxyurea.
Hydroxyzine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Hydroxyzine.
Hyoscyamine	The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Oxaliplatin.
Ibandronate	The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Oxaliplatin.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Oxaliplatin.
Ibrutinib	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ibrutinib.
Ibutilide	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ibutilide.
Icosapent ethyl	The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Oxaliplatin.
Idarubicin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Idarubicin.
Idelalisib	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Idelalisib.
Ifosfamide	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ifosfamide.
Iloperidone	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Iloperidone.
Iloprost	The risk or severity of bleeding can be increased when Iloprost is combined with Oxaliplatin.
Imatinib	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Imatinib.
Imipramine	The serum concentration of Oxaliplatin can be increased when it is combined with Imipramine.
Indacaterol	The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Oxaliplatin.
Indapamide	The risk or severity of QTc prolongation can be increased when Indapamide is combined with Oxaliplatin.
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Oxaliplatin.
Inebilizumab	The risk or severity of infection can be increased when Oxaliplatin is combined with Inebilizumab.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Oxaliplatin.
Influenza A virus A	The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Oxaliplatin.
Influenza A virus A	The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Oxaliplatin.
Influenza A virus A	The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Oxaliplatin.
Influenza A virus	The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Oxaliplatin.
Influenza A virus A	The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Oxaliplatin.
Influenza A virus	The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Oxaliplatin.
Influenza A virus	The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Oxaliplatin.
Influenza A virus A	The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Oxaliplatin.
Influenza A virus A	The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Oxaliplatin.
Influenza B virus B	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Oxaliplatin.
Influenza B virus B	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Oxaliplatin.
Influenza B virus B	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Oxaliplatin.
Influenza B virus	The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Oxaliplatin.
Inotersen	The risk or severity of QTc prolongation can be increased when Inotersen is combined with Oxaliplatin.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Oxaliplatin.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Oxaliplatin.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Oxaliplatin.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Oxaliplatin.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Oxaliplatin.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Oxaliplatin.
Interferon gamma-1b	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Oxaliplatin.
Irinotecan	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Irinotecan.
Isavuconazole	The serum concentration of Oxaliplatin can be increased when it is combined with Isavuconazole.
Isoflurane	The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Oxaliplatin.

You Might Also Read Toxine botulinum A; Uses, Dosage, Side Effect, Interactions

Istradefylline	Istradefylline may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Itraconazole	Itraconazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Ivabradine	Ivabradine may increase the QTc-prolonging activities of Oxaliplatin.
Ivosidenib	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ivosidenib.
Ixabepilone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ixabepilone.
Ixekizumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ixekizumab.
Janssen COVID-19	The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Oxaliplatin.
Japanese encephalitis	The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Oxaliplatin.
Ketoconazole	The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Oxaliplatin.
Lacidipine	The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Oxaliplatin.
Lamotrigine	The serum concentration of Oxaliplatin can be increased when it is combined with Lamotrigine.
Lansoprazole	Lansoprazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Lapatinib	The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Oxaliplatin.
Lasmiditan	The serum concentration of Oxaliplatin can be increased when it is combined with Lasmiditan.
Ledipasvir	Ledipasvir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Lefamulin	Lefamulin may increase the QTc-prolonging activities of Oxaliplatin.
Leflunomide	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Leflunomide.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Oxaliplatin.
Lenvatinib	The serum concentration of Oxaliplatin can be increased when it is combined with Lenvatinib.
Lepirudin	The risk or severity of bleeding can be increased when Lepirudin is combined with Oxaliplatin.
Letermovir	Letermovir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Leuprolide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Oxaliplatin.
Levacetylmethadol	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Levacetylmethadol.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Levobupivacaine.
Levocabastine	The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Oxaliplatin.
Levocetirizine	The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Oxaliplatin.
Levofloxacin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Levofloxacin.
Levoketoconazole	The serum concentration of Oxaliplatin can be increased when it is combined with Levoketoconazole.
Levomenthol	The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Oxaliplatin.
Levosimendan	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Levosimendan.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Lidocaine.
Lidoflazine	The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Oxaliplatin.
Linagliptin	The serum concentration of Oxaliplatin can be increased when it is combined with Linagliptin.
Linezolid	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Linezolid.
Lipegfilgrastim	Oxaliplatin may increase the myelosuppressive activities of Lipegfilgrastim.
Lofexidine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Lofexidine.
Lomefloxacin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Lomefloxacin.
Lomustine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Lomustine.
Loperamide	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Loperamide.
Lopinavir	The serum concentration of Oxaliplatin can be increased when it is combined with Lopinavir.
Losartan	The risk or severity of QTc prolongation can be increased when Losartan is combined with Oxaliplatin.
Lumefantrine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Lumefantrine.
Lurasidone	The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Oxaliplatin.
Macimorelin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Macimorelin.
Magnesium	The serum concentration of Magnesium can be decreased when it is combined with Oxaliplatin.
Maprotiline	The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Oxaliplatin.
Maribavir	Maribavir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Measles virus	The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Oxaliplatin.
Mechlorethamine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mechlorethamine.
Mefloquine	The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Oxaliplatin.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Meloxicam.
Melphalan	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Melphalan.
Meningococcal	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Oxaliplatin.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Mepivacaine.
Mepolizumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mepolizumab.
Meprednisone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Meprednisone.
Mepyramine	The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Oxaliplatin.
Mercaptopurine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mercaptopurine.
Mesoridazine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mesoridazine.
Methadone	The risk or severity of QTc prolongation can be increased when Methadone is combined with Oxaliplatin.
Methimazole	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Methimazole.
Methotrexate	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Methotrexate.
Methotrimeprazine	The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Oxaliplatin.
Methoxy	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Oxaliplatin.
Methsuximide	The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Oxaliplatin.
Methylene blue	The serum concentration of Oxaliplatin can be increased when it is combined with Methylene blue.
Methylprednisolone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Methylprednisolone.
Metoclopramide	The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Oxaliplatin.
Metoprolol	The serum concentration of Oxaliplatin can be increased when it is combined with Metoprolol.
Metronidazole	The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Oxaliplatin.
Mifepristone	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mifepristone.
Mirabegron	The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Oxaliplatin.
Mirtazapine	The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Oxaliplatin.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Oxaliplatin.
Mitoxantrone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mitoxantrone.
Mizolastine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mizolastine.
Mobocertinib	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mobocertinib.
COVID-19 Vaccine	The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Oxaliplatin.
Modified vaccinia ankara	The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Oxaliplatin.
Moexipril	The risk or severity of QTc prolongation can be increased when Moexipril is combined with Oxaliplatin.
Mometasone furoate	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mometasone furoate.
Monomethyl fumarate	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Monomethyl fumarate.
Moricizine	The risk or severity of QTc prolongation can be increased when Moricizine is combined with Oxaliplatin.
Mosunetuzumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mosunetuzumab.
Moxifloxacin	The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Oxaliplatin.
Mumps virus	The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Oxaliplatin.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Oxaliplatin.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mycophenolate mofetil.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mycophenolic acid.
Nadroparin	The risk or severity of bleeding can be increased when Nadroparin is combined with Oxaliplatin.
Nalidixic acid	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Nalidixic acid.
Natalizumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Natalizumab.
Nelarabine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Nelarabine.
Nelfinavir	Nelfinavir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Nicardipine	The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Oxaliplatin.
Nicotine	The serum concentration of Oxaliplatin can be increased when it is combined with Nicotine.
Nifedipine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Nifedipine.
Nilotinib	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Nilotinib.
Nilvadipine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Nilvadipine.

Nimodipine	The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Oxaliplatin.
Nitrendipine	The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Oxaliplatin.
Norepinephrine	The serum concentration of Oxaliplatin can be increased when it is combined with Norepinephrine.
Norfloxacin	The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Oxaliplatin.
Nortriptyline	The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Oxaliplatin.
Novobiocin	Novobiocin may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Nuvaxovid	The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Oxaliplatin.
Obinutuzumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Obinutuzumab.
Ocrelizumab	Ocrelizumab may increase the immunosuppressive activities of Oxaliplatin.
Octreotide	The risk or severity of QTc prolongation can be increased when Octreotide is combined with Oxaliplatin.
Ofatumumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ofatumumab.
Ofloxacin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ofloxacin.
Olanzapine	The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Oxaliplatin.
Olaparib	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Olaparib.
Olodaterol	The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Oxaliplatin.
Omeprazole	Omeprazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Ondansetron	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ondansetron.
Orphenadrine	The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Oxaliplatin.
Osimertinib	Osimertinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Oteseconazole	The serum concentration of Oxaliplatin can be increased when it is combined with Oteseconazole.
Oxatomide	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Oxatomide.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Oxetacaine.
Oxprenolol	The serum concentration of Oxaliplatin can be increased when it is combined with Oxprenolol.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Oxybuprocaine.
Oxytocin	The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Oxaliplatin.
Ozanimod	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ozanimod.
Paclitaxel	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Paclitaxel.
Pacritinib	The serum concentration of Oxaliplatin can be increased when it is combined with Pacritinib.
Palbociclib	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Palbociclib.
Palifermin	The therapeutic efficacy of Palifermin can be decreased when used in combination with Oxaliplatin.
Paliperidone	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Paliperidone.
Panobinostat	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Panobinostat.
Pantoprazole	Pantoprazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Papaverine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Papaverine.
Paritaprevir	Paritaprevir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Parnaparin	The risk or severity of bleeding can be increased when Parnaparin is combined with Oxaliplatin.
Pasireotide	The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Oxaliplatin.
Pazopanib	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pazopanib.
Pefloxacin	The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Oxaliplatin.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Oxaliplatin.
Pegcetacoplan	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pegcetacoplan.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Oxaliplatin.
Peginterferon alfa	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Oxaliplatin.
Peginterferon alf	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Oxaliplatin.
Peginterferon beta	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Peginterferon beta-1a.
Pemetrexed	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pemetrexed.
Penicillamine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Penicillamine.
Pentamidine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Pentamidine.
Pentosan polysulfate	The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Oxaliplatin.
Pentostatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pentostatin.
Pentoxifylline	The risk or severity of bleeding can be increased when Pentoxifylline is combined with Oxaliplatin.
Perflutren	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Perflutren.
Perhexiline	The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Oxaliplatin.
Pertussis vaccine	The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Oxaliplatin.
Phenformin	The serum concentration of Oxaliplatin can be increased when it is combined with Phenformin.
Phenindione	The risk or severity of bleeding can be increased when Phenindione is combined with Oxaliplatin.
Pheniramine	The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Oxaliplatin.
Phenol	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Phenol.
Phenoxybenzamine	The serum concentration of Oxaliplatin can be increased when it is combined with Phenoxybenzamine.
Phenprocoumon	The risk or severity of bleeding can be increased when Phenprocoumon is combined with Oxaliplatin.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Oxaliplatin.
Phenytoin	Oxaliplatin can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pibrentasvir	Pibrentasvir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaliplatin.
Pimozide	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Pimozide.
Pinaverium	The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Oxaliplatin.
Pirfenidone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pirfenidone.
Pitolisant	Oxaliplatin may increase the QTc-prolonging activities of Pitolisant.
Polythiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Oxaliplatin.
Pomalidomide	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pomalidomide.
Ponatinib	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ponatinib.
Ponesimod	The risk or severity of bradycardia can be increased when Ponesimod is combined with Oxaliplatin.
Posaconazole	The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Oxaliplatin.
Pralatrexate	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pralatrexate.
Pralsetinib	Pralsetinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Pramocaine.
Prasugrel	The risk or severity of bleeding can be increased when Prasugrel is combined with Oxaliplatin.
Pravastatin	Pravastatin may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Prednisolone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Prednisolone.
Prednisone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Prednisone.
Pregabalin	The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Oxaliplatin.
Prenylamine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Prenylamine.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Prilocaine.
Primaquine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Primaquine.
Probenecid	The serum concentration of Oxaliplatin can be increased when it is combined with Probenecid.
Probucol	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Probucol.
Procainamide	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Procainamide.
Procaine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Procaine.
Procarbazine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Procarbazine.
Prochlorperazine	The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Oxaliplatin.
Progesterone	The serum concentration of Oxaliplatin can be increased when it is combined with Progesterone.
Promazine	The risk or severity of QTc prolongation can be increased when Promazine is combined with Oxaliplatin.
Promethazine	The risk or severity of QTc prolongation can be increased when Promethazine is combined with Oxaliplatin.
Propafenone	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Propafenone.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Proparacaine.
Propofol	The risk or severity of QTc prolongation can be increased when Propofol is combined with Oxaliplatin.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Propoxycaine.
Propranolol	The serum concentration of Oxaliplatin can be increased when it is combined with Propranolol.
Propylthiouracil	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Propylthiouracil.

Protein C	The risk or severity of bleeding can be increased when Protein C is combined with Oxaliplatin.
Protein S human	The risk or severity of bleeding can be increased when Protein S human is combined with Oxaliplatin.
Protriptyline	The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Oxaliplatin.
Quetiapine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Quetiapine.
Quinidine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Quinidine.
Quinine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Quinine.
Rabeprazole	Rabeprazole may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Rabies immune	The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Oxaliplatin.
Rabies virus inactivated	The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Oxaliplatin.
Rabies virus inactivated	The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Oxaliplatin.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Oxaliplatin.
Ranitidine	The serum concentration of Oxaliplatin can be increased when it is combined with Ranitidine.
Ranolazine	The serum concentration of Oxaliplatin can be increased when it is combined with Ranolazine.
Ravulizumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ravulizumab.
Regorafenib	Regorafenib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Relugolix	The risk or severity of QTc prolongation can be increased when Relugolix is combined with Oxaliplatin.
Reteplase	The risk or severity of bleeding can be increased when Reteplase is combined with Oxaliplatin.
Reviparin	The risk or severity of bleeding can be increased when Reviparin is combined with Oxaliplatin.
Ribociclib	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ribociclib.
Rilonacept	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Rilonacept.
Rilpivirine	Rilpivirine may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Ripretinib	Ripretinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Risankizumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Risankizumab.
Risperidone	The risk or severity of QTc prolongation can be increased when Risperidone is combined with Oxaliplatin.
Ritonavir	Ritonavir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Oxaliplatin.
Rivaroxaban	The risk or severity of bleeding can be increased when Rivaroxaban is combined with Oxaliplatin.
Roflumilast	Roflumilast may increase the immunosuppressive activities of Oxaliplatin.
Rolapitant	Rolapitant may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Romidepsin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Romidepsin.
Ropeginterferon alfa	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ropeginterferon alfa-2b.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Ropivacaine.
Rosoxacin	The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Oxaliplatin.
Rotavirus vaccine	The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Oxaliplatin.
Roxadustat	The serum concentration of Oxaliplatin can be increased when it is combined with Roxadustat.
Roxithromycin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Roxithromycin.
Rubella virus vaccine	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Oxaliplatin.
Rucaparib	Rucaparib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Rupatadine	The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Oxaliplatin.
Ruxolitinib	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ruxolitinib.
Safinamide	Safinamide may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Salbutamol	The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Oxaliplatin.
Salmeterol	The serum concentration of Oxaliplatin can be increased when it is combined with Salmeterol.
Saquinavir	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Saquinavir.
Sarilumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sarilumab.
Satralizumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Satralizumab.
Secukinumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Secukinumab.
Sevoflurane	The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Oxaliplatin.
Siltuximab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Siltuximab.
Simeprevir	Simeprevir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Siponimod	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Siponimod.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Oxaliplatin.
Sirolimus	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sirolimus.
Smallpox	The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Oxaliplatin.
Sodium citrate	The risk or severity of bleeding can be increased when Sodium citrate is combined with Oxaliplatin.
Solifenacin	The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Oxaliplatin.
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Oxaliplatin.
Sotagliflozin	Sotagliflozin may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Sotalol	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Sotalol.
Sparfloxacin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Sparfloxacin.
Spesolimab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Spesolimab.
Stiripentol	The excretion of Oxaliplatin can be decreased when combined with Stiripentol.
Streptokinase	The risk or severity of bleeding can be increased when Streptokinase is combined with Oxaliplatin.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Oxaliplatin.
Sulfamethoxazole	The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Oxaliplatin.
Sulfasalazine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sulfasalazine.
Sulfinpyrazone	The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Oxaliplatin.
Sulfisoxazole	The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Oxaliplatin.
Sulodexide	The risk or severity of bleeding can be increased when Sulodexide is combined with Oxaliplatin.
Sulpiride	The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Oxaliplatin.
Sultopride	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Sultopride.
Sunitinib	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sunitinib.
Tacrolimus	Tacrolimus may increase the immunosuppressive activities of Oxaliplatin.
Tafamidis	The serum concentration of Oxaliplatin can be increased when it is combined with Tafamidis.
Tafenoquine	The serum concentration of Oxaliplatin can be increased when it is combined with Tafenoquine.
Tamoxifen	The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Oxaliplatin.
Taurocholic acid	Taurocholic acid may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Tedizolid phosphate	The risk or severity of myelosuppression can be increased when Oxaliplatin is combined with Tedizolid phosphate.
Telavancin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Telavancin.
Telithromycin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Telithromycin.
Telmisartan	Telmisartan may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Temozolomide	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Temozolomide.
Temsirolimus	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Temsirolimus.
Tenecteplase	The risk or severity of bleeding can be increased when Tenecteplase is combined with Oxaliplatin.
Teniposide	The risk or severity of adverse effects can be increased when Teniposide is combined with Oxaliplatin.
Tepotinib	Tepotinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Teprotumumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Teprotumumab.
Terbutaline	The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Oxaliplatin.
Terfenadine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Terfenadine.
Teriflunomide	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Teriflunomide.
Terlipressin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Terlipressin.
Tetrabenazine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Tetrabenazine.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Tetracaine.
Thalidomide	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Thalidomide.
Thiamine	The serum concentration of Oxaliplatin can be increased when it is combined with Thiamine.
Thioridazine	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Thioridazine.
Thiotepa	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Thiotepa.
Thiothixene	The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Oxaliplatin.
Ticagrelor	The risk or severity of bleeding can be increased when Ticagrelor is combined with Oxaliplatin.

You Might Also Read Exemestane; Uses, Dosage, Side Effects, Interactions

Timolol	The risk or severity of QTc prolongation can be increased when Timolol is combined with Oxaliplatin.
Tinzaparin	The risk or severity of bleeding can be increased when Tinzaparin is combined with Oxaliplatin.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Oxaliplatin.
Tirofiban	The risk or severity of bleeding can be increased when Tirofiban is combined with Oxaliplatin.
Tivozanib	Tivozanib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Tixocortol	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Tixocortol.
Tizanidine	The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Oxaliplatin.
Tocilizumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Tocilizumab.
Tofacitinib	Oxaliplatin may increase the immunosuppressive activities of Tofacitinib.
Tolterodine	The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Oxaliplatin.
Topotecan	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Topotecan.
Toremifene	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Toremifene.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Oxaliplatin.
Trabectedin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Trabectedin.
Trastuzumab	Trastuzumab may increase the neutropenic activities of Oxaliplatin.
Trastuzumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Trastuzumab emtansine.
Trazodone	The risk or severity of QTc prolongation can be increased when Trazodone is combined with Oxaliplatin.
Treprostinil	The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Oxaliplatin.
Tretinoin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Tretinoin.
Triamcinolone	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Triamcinolone.
Trichlormethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Oxaliplatin.
Triclabendazole	The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Oxaliplatin.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Oxaliplatin.
Triflusal	The risk or severity of bleeding can be increased when Triflusal is combined with Oxaliplatin.
Trilaciclib	The serum concentration of Oxaliplatin can be increased when it is combined with Trilaciclib.
Trilostane	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Trilostane.
Trimebutine	The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Oxaliplatin.
Trimethadione	The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Oxaliplatin.
Trimethoprim	The serum concentration of Oxaliplatin can be increased when it is combined with Trimethoprim.
Trimipramine	The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Oxaliplatin.
Triprolidine	The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Oxaliplatin.
Triptorelin	The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Oxaliplatin.
Trovafloxacin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Trovafloxacin.
Tucatinib	The serum concentration of Oxaliplatin can be increased when it is combined with Tucatinib.
Typhoid vaccine	The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Oxaliplatin.
Typhoid Vaccine Live	The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Oxaliplatin.
Typhoid	The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Oxaliplatin.
Upadacitinib	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Upadacitinib.
Urokinase	The risk or severity of bleeding can be increased when Urokinase is combined with Oxaliplatin.
Valproic acid	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Valproic acid.
Vandetanib	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Vandetanib.
Vardenafil	The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Oxaliplatin.
Varenicline	The serum concentration of Oxaliplatin can be increased when it is combined with Varenicline.
Varicella zoster	The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Oxaliplatin.
Varicella zoster	The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Oxaliplatin.
Vedolizumab	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vedolizumab.
Velpatasvir	Velpatasvir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Vemurafenib	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Vemurafenib.
Venetoclax	Venetoclax may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Venlafaxine	Venlafaxine may increase the excretion rate of Oxaliplatin which could result in a lower serum level and potentially a reduction in efficacy.
Vernakalant	The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Oxaliplatin.
Vibrio cholerae	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Oxaliplatin.
Vilanterol	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vilanterol.
Vinblastine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vinblastine.
Vincristine	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vincristine.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Oxaliplatin.
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Oxaliplatin.
Vismodegib	Vismodegib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Voclosporin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Voclosporin.
Vorapaxar	The risk or severity of bleeding can be increased when Vorapaxar is combined with Oxaliplatin.
Voriconazole	The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Oxaliplatin.
Vorinostat	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Vorinostat.
Voxilaprevir	Voxilaprevir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Warfarin	The risk or severity of bleeding can be increased when Warfarin is combined with Oxaliplatin.
Ximelagatran	The risk or severity of bleeding can be increased when Ximelagatran is combined with Oxaliplatin.
Yellow fever vaccine	The risk or severity of infection can be increased when Yellow fever vaccine is combined with Oxaliplatin.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Oxaliplatin.
Ziprasidone	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Ziprasidone.
Zonisamide	The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Oxaliplatin.
Zuclopenthixol	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Zuclopenthixol.

Pregnancy and Lactation

US FDA pregnancy category D

Pregnancy

If you are pregnant or plan to become pregnant. Oxaliplatin may harm your unborn baby. Tell your doctor right away if you become pregnant or think you may be pregnant during treatment with oxaliplatin.

You are able to become pregnant, your doctor may do a pregnancy test before you start treatment with oxaliplatin and for 9 months after the final dose. Talk to your doctor about forms of birth control that may be right for you.

Lactation

If you are breastfeeding or plan to breastfeed. It is not known if oxaliplatin passes into your breast milk. Do not breastfeed during treatment with oxaliplatin and for 3 months after the final dose.

Females who are able to become pregnant should avoid becoming pregnant and should use effective birth control during treatment with oxaliplatin and for 9 months after the final dose. Talk to your doctor about forms of birth control that may be right for you.

Males with female partners who are pregnant or able to become pregnant should use effective birth control during treatment with oxaliplatin and for 6 months after the final dose. Oxaliplatin may cause fertility problems in males and females. Talk to your doctor if this is a concern for you.

What special precautions should I follow?

Before using oxaliplatin,

tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention oral anticoagulants (‘blood thinners) such as warfarin (Coumadin). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
tell your doctor if you have or have ever had kidney disease.
tell your doctor if you are pregnant or plan to become pregnant. Oxaliplatin may harm the fetus. You should use birth control to prevent pregnancy during your treatment with oxaliplatin. Talk to your doctor about the types of birth control that will work for you.If you become pregnant while taking oxaliplatin, call your doctor. Do not breastfeed during your treatment with oxaliplatin.
if you are having surgery, including dental surgery, tell the doctor or dentist that you are using oxaliplatin.
you should know that oxaliplatin may decrease your ability to fight infection. Stay away from people who are sick during your treatment with oxaliplatin.
you should know that exposure to cold air or objects may make some of the side effects of oxaliplatin worse. You should not eat or drink anything colder than room temperature, touch any cold objects, go near air conditioners or freezers, wash your hands in cold water, or go outside in cold weather unless absolutely necessary for five days after you receive each dose of oxaliplatin. If you must go outside in cold weather, wear a hat, gloves, and a scarf, and cover your mouth and nose.

References

https://www.cancer.gov/about-cancer/treatment/drugs/capox
https://go.drugbank.com/drugs/DB00526
https://en.wikipedia.org/wiki/Oxaliplatin
https://www.drugs.com/oxaliplatin.html
https://medlineplus.gov/druginfo/meds/a607035.html
https://pubchem.ncbi.nlm.nih.gov/compound/Oxaliplatin
https://pubchem.ncbi.nlm.nih.gov/compound/Oxaliplatine
https://www.webmd.com/drugs/2/drug-64025/oxaliplatin-intravenous/details/list-contraindications
https://www.ncbi.nlm.nih.gov/books/
ChemIDplus
LICENSE
https://www.nlm.nih.gov/copyright.html
Oxaliplatin [USAN:USP:INN:BAN]
https://chem.nlm.nih.gov/chemidplus/sid/0061825943
DrugBank
https://www.drugbank.ca/legal/terms_of_use
Oxaliplatin
https://www.drugbank.ca/drugs/DB00526
EPA DSSTox
LICENSE
https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
Oxaliplatin
https://comptox.epa.gov/dashboard/DTXSID0036760
CompTox Chemicals Dashboard Chemical Lists
https://comptox.epa.gov/dashboard/chemical-lists/
European Chemicals Agency (ECHA)
https://echa.europa.eu/web/guest/legal-notice
Oxaliplatin
https://echa.europa.eu/information-on-chemicals
Oxaliplatin
https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/154685
ClinicalTrials.gov
https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
https://clinicaltrials.gov/
DailyMed
LICENSE
https://www.nlm.nih.gov/copyright.html
OXALIPLATIN
https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=OXALIPLATIN
LiverTox
LICENSE
https://www.nlm.nih.gov/copyright.html
Oxaliplatin
https://www.ncbi.nlm.nih.gov/books/n/livertox/Oxaliplatin/
NCI Thesaurus (NCIt)
https://www.cancer.gov/policies/copyright-reuse
https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1181
Nature Chemical Biology
https://pubchem.ncbi.nlm.nih.gov/substance/46095912
Therapeutic Target Database (TTD)
Oxaliplatin
http://idrblab.net/ttd/data/drug/details/D0Y3ME
EU Clinical Trials Register
https://www.clinicaltrialsregister.eu/
FDA Orange Book
https://www.fda.gov/about-fda/about-website/website-policies#linking
https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
National Drug Code (NDC) Directory
LICENSE
https://www.fda.gov/about-fda/about-website/website-policies#linking
OXALIPLATIN
https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
NCI Cancer Drugs
LICENSE
https://www.cancer.gov/policies/copyright-reuse
Eloxatin (Oxaliplatin)
https://www.cancer.gov/about-cancer/treatment/drugs/oxaliplatin
NIPH Clinical Trials Search of Japan
https://rctportal.niph.go.jp/en/
NLM RxNorm Terminology
https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
oxaliplatin
https://rxnav.nlm.nih.gov/id/rxnorm/32592
NORMAN Suspect List Exchange
LICENSE
Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0
https://creativecommons.org/licenses/by/4.0/
NORMAN Suspect List Exchange Classification
https://www.norman-network.com/nds/SLE/
WHO Anatomical Therapeutic Chemical (ATC) Classification
https://www.whocc.no/copyright_disclaimer/
https://www.whocc.no/atc/
ATC Code
https://www.whocc.no/atc_ddd_index/
PubChem
https://pubchem.ncbi.nlm.nih.gov
Springer Nature
https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=15061931-163297434
Thieme Chemistry
LICENSE
The Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.
https://creativecommons.org/licenses/by-nc-nd/4.0/
https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=15061931-163295758
WHO Model Lists of Essential Medicines
https://www.who.int/about/who-we-are/publishing-policies/copyright
Oxaliplatin
https://list.essentialmeds.org/medicines/101
Medical Subject Headings (MeSH)
https://www.nlm.nih.gov/copyright.html
Oxaliplatin
https://www.ncbi.nlm.nih.gov/mesh/2027910
MeSH Tree
http://www.nlm.nih.gov/mesh/meshhome.html
Antineoplastic Agents
https://www.ncbi.nlm.nih.gov/mesh/68000970
UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
GHS Classification Tree
http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
EPA Substance Registry Services
LICENSE
https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
EPA SRS List Classification
https://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do

Oxaliplatin – Uses, Dosage, Side Effects, Interaction

Mechanism of Action

Indications

Contraindication